ImmunoCellular Licenses Cancer Stem Cell Technologies From Cedars-Sinai
Posted on: Thursday, 10 July 2008, 09:01 CDT
ImmunoCellular Therapeutics has exclusively licensed from Cedars-Sinai Medical Center, certain novel peptides which can stimulate the immune system to target cancer stem cells in gliomas, a cancer originating in the brain or spine.
According to the company, these peptides were specifically designed to elicit a T cell response targeting CD133 positive cancer stem cells that have been identified in a number of cancer types, including gliomas, colon cancer and pancreatic cancer.
Manish Singh, president and CEO of ImmunoCellular Therapeutics, said: "This technology allows us to leap frog to development of the next generation of cancer stem cell vaccines which could be used in an off-the-shelf manner targeting multiple cancers."
Source: Datamonitor
Related Articles
- Cancerous Stem Cells Researched
- MicroRNAs Regulate Cancer Stem Cells
- Key Research on Cancer Stem Cells and Their Relevance and Impact on Drug and Diagnostic Discovery
- Two Types of Cancer Stem Cells?
- Cancer Stem Cell Development is Documented
- Data Show Geron's Telomerase Inhibitor Cancer Drug is Active Against Cancer Stem Cells From Multiple Myeloma Patients
- Stanford Gets $20M Cancer-Stem Cell Site
- $20 Million Gift to Establish Cancer Stem Cell Research Center at Stanford
- OncoMed Pharmaceuticals Granted Fundamental Patent for Identifying Therapeutics Targeting Cancer Stem Cells
- Cancer Stem Cell Found for Tumors
 |
 |
User Comments (0)
RSS Feeds